Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 7.01
Delek Logistics closed a public offering of 4,600,000 common units (limited partner interests) at $50.00 per unit, raising approximately $220.8 million in gross proceeds. This is a registered public offering of equity securities that dilutes existing unitholders; notably, the controlling shareholder Delek Holdings did not participate, causing its ownership to decline from 63.0% to 58.0%. This is a material capital-raising event typical of dilutive equity issuances disclosed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 3.02
Interactive Strength issued 205,000 shares of Common Stock in exchange for Series A Preferred shares and promissory note principal balances on August 10 and 12, 2026. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and notes reliance on Section 3(a)(9) exemption. This represents a material dilutive issuance to existing shareholders, with the exchange shares issued at prices ranging from $3.42 to $3.58 per share, increasing outstanding shares from approximately 1.4 million to 1.6 million shares.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-14
The Company entered into a securities purchase agreement on August 13, 2026, to sell 12,000,000 American Depositary Shares at $0.45 per ADS, generating approximately $5.4 million in gross proceeds. This is a registered direct offering of equity securities to certain purchasers, which constitutes a dilutive issuance. The disclosure explicitly references incorporation into the Form F-3 registration statement, confirming this is a material capital-raising transaction that would affect investor assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-14
Item 1.01
The Company entered into an inducement letter agreement on August 14, 2026, whereby warrant holders exercise existing warrants at a reduced price ($1.20 vs. original $2.33–$3.32) in exchange for new unregistered warrants to purchase 6,015,308 shares at $0.95 per share. This is a classic dilutive private placement structure: the Company issues new equity securities (New Warrants and Placement Agent Warrants) in an unregistered offering under Section 4(a)(2), generating approximately $3.6 million in gross proceeds. The issuance of unregistered equity securities and the significant dilution (doubling the warrant shares outstanding) are hallmarks of a dilutive issuance material to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-14
The Company is issuing 728,484 Class A ordinary shares to settle US$557,289.87 in accounts payable owed by its subsidiary WTP. The issuance represents 12.28% of outstanding shares at a price (US$0.765) that is 85% of the closing Nasdaq price, constituting a dilutive equity issuance to settle debt. This is a material capital event affecting existing shareholders' ownership percentage.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 1.01
HeartBeam entered into an At-The-Market (ATM) equity offering agreement on August 14, 2026, authorizing the sale of up to $25 million in common stock through Titan Partners Securities LLC. ATM offerings are a form of registered direct equity issuance that can be dilutive to existing shareholders. The filing explicitly references the shelf Registration Statement (Form S-3) and prospectus supplement, confirming this is a registered offering of equity securities that would materially affect investor assessment of capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-14
Item 1.01
Dyadic International completed a registered direct offering of 3,625,000 shares at $0.795 per share combined with a concurrent private placement of 3,625,000 warrants to purchase additional shares, generating approximately $2.9 million in gross proceeds. This dilutive capital raise combines registered and unregistered equity securities and materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-14
Clean Energy Technologies entered into a securities purchase agreement with Pacific Pier Capital II, LP to issue a convertible promissory note with principal amount of $178,410 for net funding of $143,000.80. The Note is convertible into common stock at 85% of the lowest 10-day VWAP, with an Exchange Cap of 2,000,000 shares pending shareholder approval. This is a dilutive equity issuance (convertible debt) raising capital through an unregistered private placement under Section 4(a)(2), which is material to investors as it signals potential equity dilution and capital-raising pressure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
The filing discloses a private placement of 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof) together with warrants to purchase an additional 16,924,054 shares, raising approximately $4.0 million in gross proceeds. Item 1.01 describes entry into a material definitive securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a small-cap biotechnology company raising capital through a private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 3.02
The Company issued 1,433,927 shares of Class A common stock to Liquidity Event Partners in reliance on Section 4(a)(2) exemption from registration, constituting an unregistered equity issuance. This is a material dilutive event for shareholders, particularly significant given the Company's recent IPO (May 19, 2026) and the substantial share count involved. The disclosure is properly filed under Item 3.02, which governs unregistered sales of equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 3.02
In connection with the Redx acquisition, Skye is issuing unregistered equity securities comprising approximately $125 million in aggregate gross proceeds from a PIPE Financing (~$68M), Series A Financing (~$36M), and an Equity Line Facility warrant ($5M), issued under Section 3(a)(10) and Section 4(a)(2) exemptions. The concurrent financing will result in new investors owning approximately 48.45% of the combined company post-closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 8.01
Zentalis entered into an underwriting agreement to issue and sell 23,000,000 shares of common stock at $3.50 per share, with an additional 3,450,000-share option granted to underwriters. This is a registered public offering of equity securities generating approximately $75.1 million in net proceeds. While technically registered (via Form S-3), the scale and dilutive impact to existing shareholders make this a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-14
Item 8.01
RadNet filed a prospectus supplement to register 34,069 shares of common stock for resale by See-Mode Sellers as payment for milestone conditions under a Share Purchase Agreement. This represents a dilutive equity issuance to former acquisition targets, which materially affects shareholder equity and voting power. While the shares are being registered for resale rather than newly issued, the disclosure centers on the registration of shares to be issued as acquisition consideration, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-13
Item 3.02
Vireo Growth issued approximately 3,004,751 subordinate voting shares as consideration in the PharmaCann acquisition, representing approximately $48.7 million in equity consideration in a transaction exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-13
EX-99.4
Vertical Aerospace amended and restated its Securities Purchase Agreement with YA II PN, Ltd. on August 12, 2026, for the sale of up to $250 million in Series A Convertible Preferred Shares convertible into Ordinary Shares in a private placement structured with multiple closings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-13
Item 8.01
Delek Logistics announced the pricing of an underwritten public offering of 4,000,000 common units at $50.00 per unit, with an additional 600,000-unit option granted to underwriters. This is a registered public offering of equity securities that will dilute existing unitholders' ownership; the parent company Delek Holdings' stake will decline from 63.0% to approximately 58.0%. The filing explicitly states the offering is made pursuant to an effective shelf registration statement, and the press release was issued in accordance with Rule 134 under the Securities Act.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-13
Item 3.02
Lithium Americas issued common shares and convertible debentures to YA II PN, Ltd. pursuant to a Purchase Agreement, relying on Section 4(a)(2) exemption from registration. The issuance of equity and equity-linked securities constitutes a dilutive capital raise material to investors assessing ownership structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-13
Veea Inc. entered into an At Market Issuance Sales Agreement (ATM Agreement) with Roth Capital Partners on August 13, 2026, authorizing the sale of up to $4,353,000 in common stock shares through an at-the-market offering under an existing Form S-3 registration statement. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-13
Item 1.01
Zoomcar entered into securities purchase agreements on July 27, 2026, issuing 498 Series A Convertible Preferred Shares and 498 Warrants (exercisable for 9.96 million common shares) in a private placement under Section 4(a)(2) and Regulation D Rule 506(c), with up to $5 million in units plus a $5 million overallotment option. The offering includes unregistered sales of Units, Preferred Shares, Warrants, and Placement Agent Warrants, with significant potential dilution to existing shareholders through conversion and warrant exercise rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-13
Item 1.01
CapsoVision entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald for an at-the-market offering program permitting sale of up to $100 million in common stock, representing a material capital-raising mechanism that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-13
Item 7.01
The filing discloses Rocket Lab's entry into an equity distribution agreement (ATM program) with an aggregate offering price of $1,944,369,826 in common stock. While the company intends to use proceeds to fund the Iridium acquisition and reduce debt, the core disclosure is the establishment of a new equity issuance facility that permits substantial dilution to existing shareholders. The press release explicitly states this is a "replacement" ATM program carrying forward unsold amounts, and the company "may offer and sell" shares at market prices, making this a dilutive equity issuance material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-12
Item 8.01
American Express closed the sale of 1,600 Depositary Shares representing Series E Preferred Shares on August 12, 2026, pursuant to an underwriting agreement, creating a new preferred equity security with fixed-rate dividend obligations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
EX-99.1
The exhibit discloses a private placement of 5,828,342 special warrants closed on July 30, 2026, for aggregate gross proceeds of approximately US$25 million. The special warrants will automatically convert into common shares and common share purchase warrants, creating significant dilution to existing shareholders. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and the magnitude (US$25M) and structure (warrant-based conversion) make it material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-12
Item 3.02
APPlife Digital Solutions issued a $170,000 convertible promissory note to an accredited investor under Regulation D. The note is convertible into common stock at a 35% discount to the lowest trading price during the preceding 20 trading days, with conversion rights commencing six months after issuance, resulting in equity dilution upon conversion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-12
Item 8.01
Lucid registered for resale approximately 75.7 million shares of Class A Common Stock (51.7 million from conversion of Series C Convertible Preferred Stock and 24.0 million issued to SMB/Uber subsidiary) plus 55,000 shares of Series C Convertible Preferred Stock. Although the filing emphasizes "no new shares will be issued," the registration of these previously-issued private placement shares for resale creates material dilution risk to existing shareholders. The involvement of major investors (Saudi Arabia's Public Investment Fund via Ayar and Uber Technologies via SMB) and the substantial share count make this a material capital event affecting shareholder value.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
Ryman Hospitality Properties entered into an underwriting agreement on August 10, 2026, to issue 5,100,000 shares of common stock at $117.00 per share in a registered public offering, with underwriters exercising a 30-day option for an additional 765,000 shares on August 11, 2026. The offering closed on August 12, 2026, generating approximately $658 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital-raising event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 1.01
OLB Group entered into an Equity Distribution Agreement with Maxim Group LLC on August 7, 2026, establishing an "at-the-market offering" (ATM) program to sell up to $1,600,000 of common stock shares. This is a classic dilutive equity issuance under Rule 415, where the company retains discretion over timing and volume but commits to a registered offering program that will dilute existing shareholders. The prospectus supplement filed on August 7, 2026, registered the shares for sale, making this a material capital-raising event typical of small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 8.01
Intel announced and entered into an underwriting agreement for a $20 billion registered public offering of approximately 210.5 million shares of common stock at $95 per share, with underwriters holding a 30-day option to purchase an additional 31.6 million shares. Net proceeds of approximately $19.7 billion are intended for general corporate purposes including capital expenditures and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 8.01
Delek Logistics announced commencement of an underwritten public offering of $175 million of common units (with an additional $26.25 million option), representing limited partner interests in the partnership. This is a material equity issuance that will dilute existing unitholders. The proceeds are intended to repay debt and for general partnership purposes, which is typical for capital raises by MLPs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
ACRES Commercial Realty Corp. entered into a Securities Purchase Agreement on August 10, 2026, to issue 2,220,000 shares of Series C Cumulative Redeemable Preferred Stock at $23.75 per share, generating approximately $52.75 million in gross proceeds. Although the offering was registered (via Form S-3), the issuance of preferred stock with fixed-to-floating dividend terms represents a material capital raise that dilutes existing equity holders and signals the company's need to raise capital. This is a material event affecting the registrant's capital structure and financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 8.01
American Healthcare REIT closed a public offering of 13,250,000 shares of common stock on August 12, 2026, structured as a forward sale with underwriters borrowing and selling shares to hedge forward purchasers' obligations. The filing explicitly states the company intends to contribute net proceeds to its operating partnership for a pending acquisition of senior housing properties and general corporate purposes. This is a material equity issuance that will dilute existing shareholders and fund significant capital deployment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-12
Item 1.01
Silence Therapeutics entered into an underwriting agreement on August 11, 2026 to issue and sell approximately 12.96 million ADSs at $13.50 per ADS, generating approximately $164.0 million in net proceeds (or $188.7 million if the underwriters' 30-day option to purchase up to 1.94 million additional ADSs is fully exercised). This registered public offering will dilute existing shareholders and materially affect the company's capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Jumia entered into a Subscription Agreement with the International Finance Corporation (IFC) to issue 9,057,970 new ordinary bearer shares (as ADSs) for approximately US$25 million, and concurrent Share Purchase Agreements with other investors (including Axian) for 4,528,983 new ADSs for approximately US$25 million, totaling US$50 million in gross proceeds. The shares are being issued outside the registered offering framework under Securities Act exemptions, and certain investors have been granted registration rights. This is a material unregistered equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
CleanCore priced a public offering of 275.8 million shares of common stock, 124.2 million pre-funded warrants, and 400 million investor warrants for approximately $100 million in gross proceeds. The offering includes substantial warrant issuances (524.2 million warrants total) that are immediately or near-immediately exercisable, creating significant dilution to existing shareholders. The 90-day lock-up on new issuances and 180-day restriction on variable rate transactions further confirm the dilutive nature of this capital raise. This is a material equity issuance that would substantially affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
The Company entered into securities purchase agreements on August 11, 2026, to issue 2,000,000 ordinary shares at $0.90 per share for gross proceeds of $1.8 million in a private investment in public equity transaction under Regulation S. This is an unregistered equity issuance that will dilute existing shareholders, with closing expected August 27, 2026. The transaction includes a material insider purchase by Chairman Zheng Jiahua of 500,000 shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-08-12
Item 1.01
OS Therapies entered into a securities purchase agreement on August 10, 2026, to issue senior secured convertible promissory notes totaling up to $10,000,000 in a private placement, with the initial tranche of $5,000,000 already closed. The offering includes common stock, pre-funded warrants, and five-year warrants, creating substantial dilution to existing shareholders through unregistered sales of equity securities under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Ticketplus Ltd. completed an initial public offering on August 10, 2026, issuing 1,875,000 ordinary shares at $8.00 per share for $15 million in gross proceeds, followed by partial exercise of a 45-day over-allotment option on August 12, 2026, for an additional 258,814 shares generating approximately $2.07 million in gross proceeds. This is a material equity issuance event that dilutes existing shareholders and raises capital for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
Sky Harbour Group entered into a Stock Purchase Agreement on August 10, 2026, to sell 4,000,000 shares of Class A common stock at $10.00 per share in a registered direct offering, closing on August 12, 2026, and raising $40.0 million in gross proceeds. While technically a registered offering (not unregistered), the disclosure of a material equity issuance with dilutive impact to existing shareholders is most closely aligned with dilutive_issuance in the taxonomy. The 90-day lock-up provision and concurrent secondary transactions by Boston Omaha Corporation further underscore the capital-raising nature of this transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-12
The filing discloses entry into a Strategic Share Issuance Agreement under which Fusemachines will issue up to 1,250,000 shares of common stock to Qintess in three tranches, contingent on Qintess achieving minimum service spend thresholds under a Master License and Services Agreement. Item 3.02 explicitly classifies this as an unregistered sale of equity securities under Section 4(a)(2) and Regulation D. While the agreement also involves a material commercial relationship with $6.5 million in committed services spend, the primary 8-K disclosure mechanism and the explicit Item 3.02 filing indicate the equity issuance is the material event being reported.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-12
ENvue Medical entered into a Common Shares Purchase Agreement on August 12, 2026, establishing a committed equity facility of up to $50 million whereby the Company can sell common stock to an institutional investor at 90% of the three-day volume-weighted average price. This is a classic at-the-market (ATM) or committed equity offering structure that allows the Company to raise capital through dilutive equity issuance at its discretion. The filing also discloses a Second Amendment to a prior Series H Preferred Stock purchase agreement increasing additional investment rights to $59 million. Both transactions represent material dilutive equity issuances typical of small- and mid-cap companies raising capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
The filing discloses a completed private placement of 1,373,152 shares of common stock at $3.00 per share for $4.12 million in gross proceeds, sold to accredited investors and non-U.S. persons under Section 4(a)(2), Rule 506(b), and Regulation S exemptions. Items 1.01 and 3.02 explicitly address the unregistered sale of equity securities, which is the defining characteristic of a dilutive issuance. The shares are restricted and the company committed to file a resale registration statement within 90 days.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Core AI Holdings entered into a Market Issuance Sales Agreement on August 11, 2026, to sell up to $3,539,021 of common shares through an at-the-market (ATM) offering program. This is a dilutive equity issuance under an effective shelf registration statement (Form F-3), which would materially affect existing shareholders through dilution and is a material capital-raising event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 3.02
Workhorse sold 1.5 million unregistered warrants to MGMH in reliance on Section 4(a)(2) and Rule 506 exemptions as part of the credit facility amendment. The warrants are restricted securities bearing restrictive legends and represent a dilutive equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 3.02
On August 6-7, 2026, the Company entered into Amendment No. 2 to a Securities Purchase Agreement with GHS Investments, LLC, authorizing the issuance of up to 207 shares of Series D Convertible Preferred Stock, with an immediate Fourth Additional Closing on August 7, 2026, issuing 40 shares (37 purchased for $37,000 plus 3 as equity incentive) under Section 4(a)(2) and Regulation D Rule 506(b) exemptions to an accredited investor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 3.02
The filing discloses an unregistered sale of equity securities under Item 3.02, specifically the issuance of 308,655 shares of Series A Convertible Preferred Stock in a Rule 506(b) private placement during July-August 2026, generating $3,042,000 in gross proceeds. This is a classic dilutive issuance of convertible preferred equity to accredited investors, material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 3.02
OceanLight executed an unregistered private placement of 211,250 units to the Sponsor at $10.00 per unit, generating $2.1125 million in gross proceeds, pursuant to Section 4(a)(2) exemption, concurrent with the IPO.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-11
EX-99.1
Apollomics announced a $10 million private placement of unregistered Class A ordinary shares comprising 700,001 shares issued under Section 4(a)(2) and Regulation D Rule 506. The transaction includes $8 million in cash subscriptions at $15/share plus $2 million in convertible note conversion at $12/share. This is a classic dilutive equity issuance to raise capital, with participation from insiders (CEO Chen, CFO Lin, COO Chen affiliate), characteristic of a PIPE-like transaction material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-11
Item 3.02
RYTHM sold unregistered equity securities to RSLGH (a Green Thumb subsidiary), including amended convertible notes, warrants, and underlying common stock in reliance on Section 4(a)(2) and Regulation D Rule 506(b), with aggregate consideration of $109.5 million.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-11
The 6-K discloses a partial exercise of an Additional Allocation Option under a securities purchase agreement, resulting in the issuance of 454,545 Class A Ordinary Shares on August 6, 2026. This represents a dilutive equity issuance at US$1.10 per share, following an earlier registered direct offering in July 2026. The disclosure of new share issuance and the resulting change in outstanding shares (to 8,666,755) constitutes a material capital event affecting shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-11
Item 1.01
Main Street Capital entered into new equity distribution agreements with Academy Securities and SMBC Nikko Securities to add them as sales agents under its existing "at the market" (ATM) equity offering program, authorizing the issuance of up to 20,000,000 shares of common stock. While the filing emphasizes that Main Street "may, but has no obligation to" issue shares, the establishment of an ATM offering program with multiple sales agents represents a material dilutive issuance arrangement that would affect investor assessment of potential share dilution and capital-raising capacity.
View raw filing on EDGAR →